Tiziana Life Sciences Ltd (FRA:0RP)

Germany flag Germany · Delayed Price · Currency is EUR
1.390
+0.100 (7.75%)
Last updated: Jan 20, 2026, 8:03 AM CET
107.46%
Market Cap162.21M +94.3%
Revenue (ttm)n/a
Net Income-10.93M
EPS-0.10
Shares Outn/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volumen/a
Open1.390
Previous Close1.290
Day's Range1.390 - 1.390
52-Week Range0.615 - 2.140
Betan/a
RSI48.05
Earnings DateMay 4, 2026

About Tiziana Life Sciences

Tiziana Life Sciences Ltd, a biotechnology company, engages in the development of transformative therapies for neurodegenerative and lung diseases in the United States. The company’s lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for use in the treatment of Crohn’s, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It is also developing TZLS-501, a fully human mAb targeting the IL-6 receptor for u... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1998
Employees 9
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 0RP
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements